Biogen
Update in progressBIIB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Biogen discovers, develops, manufactures and markets therapies worldwide for neurological and autoimmune diseases. Its portfolio includes MS drugs TECFIDERA, AVONEX, PLEGRIDY and TYSABRI; SPINRAZA for spinal muscular atrophy; LEQEMBI for Alzheimer's; SKYCLARYS, QALSODY, FUMADERM, ZURZUVAE; anti-CD20 medicines RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO and glofitamab; and several biosimilars. The company collaborates with many partners and was founded in 1978 in Cambridge, MA.
Company score
- Sentiment
- 1.91
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.21
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.89
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.63
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Christopher A. Viehbacher
- Founded1978
- Employees7,500
- Websitewww.biogen.com
Identifiers
- ISINUS09062X1037
- FIGIBBG000C17X76
- LEIW8J5WZB5IY3K0NDQT671
- CUSIP09062X103
- CIK0000875045